ОЦЕНКА ПЕРЕНОСИМОСТИ И ЭФФЕКТИВНОСТИ НОВОГО ФИКСИРОВАННОГО КОМБИНИРОВАННОГО ПРАПАРАТА ПРИ ПЕРВИЧНОЙ ОТКРЫТОУГОЛЬНОЙ ГЛАУКОМЕ
Litsenziya: cc-by-nc-nd
Annotatsiya
Relevance. The main goal of glaucoma treatment is to lower IOP to a level that prevents or minimizes progressive vision loss. Purpose of the study. To evaluate the antihypertensive efficacy and safety of the fixed combination drug Simbrinza in primary open-angle glaucoma. Material and methods. All 15 (30 eyes) patients underwent standard ophthalmological examinations. On the instructions of the Pharmaceutical Committee and the Committee on Bioethics of the Republic of Uzbekistan, clinical trials have begun to study the hypotensive efficacy and tolerability of Simbrinza (manufactured by Novartis Pharma, AG (Switzerland)) in patients with open-angle glaucoma with high IOP. Results and conclusion. It was found that Simbrinza effectively and quickly reduces IOP to 45% of the initial level, and a high hypotensive effect persists for 3 to 6 months. The drug is recommended for short-term therapy of patients with ОАG and ophthalmohypertension. After reaching the “target pressure”, patients are recommended to be transferred to a more stable combination. According to the survey data, 93.4% of patients rated the drug as comfortable and convenient for use. The frequency of systemic and local side effects do not differ from other ophthalmohypotensive drugs.
Hali tarjima qilinmagan